Today: 18 June 2026
Browse Category

Stock Market 25 February 2026

CervoMed shares rose after the company received a U.S. patent allowance for neflamapimod in pure dementia with Lewy bodies, with the patent expected to last until 2042. Corning shares rebounded, driven by investor focus on its optical-fiber and photonics exposure to AI data-center spending. Amazon climbed about 2.4% after reports it is in talks to sell its custom AI chips to outside data centers. Butterfly Network surged over 50% at one point after Midjourney built a full-body ultrasound scanner from Butterfly modules, highlighting a licensing and co-development deal that could bring Butterfly up to $74 million. SpaceX’s public-market debut has created tax and diversification challenges for tech workers with stock-heavy compensation. Taiwan’s Taiex closed at a record high, with TSMC gaining 1.05% and its U.S. ADR rising 6.3%, boosting chip stocks. Grab rose 2.6% amid higher Q1 profit and a $500 million buyback, though investors remain cautious. Strategy’s Stretch preferred stock traded below its $100 target, which is significant for the company’s bitcoin funding strategy. U.S. gas prices fell below $4, the lowest since March, after a U.S.-Iran interim deal aimed at reopening the Strait of Hormuz. Salesforce shares remained under pressure despite record results and strong AI-driven recurring revenue, with concerns about its $3.6 billion Fin deal and integration risks. CDT Equity shares surged after a private investment in Sarborg, though risks remain from a new convertible loan and upcoming Nasdaq listing. Hyperscale Data shares climbed around 8%, with trading linked to AI data center and Bitcoin updates. Pfizer fell 3.2% after announcing CFO Dave Denton’s departure, as investors focus on 2026 guidance and upcoming changes. The S&P 500, Nasdaq, and Dow all posted gains, while Brent crude dropped and the U.S. 10-year Treasury yield eased. Intel led chip stocks higher after news that Apple will team up with Intel on U.S. chip production. Apple shares gained after CEO Tim Cook said product price hikes are unavoidable due to higher chip costs. IBM fell 6.9% after Accenture’s weak sales forecast and concerns from IBM’s AI report about control over AI outcomes. QuantumScape rose 5.7% after Honda R&D agreed to a multi-year solid-state battery research program, though execution risk remains. Energy Fuels rose 10% after a conditional U.S. government loan commitment fo
Stock market today: Dow futures steady as AI scare cools, Nvidia earnings and Trump tariffs loom

Stock market today: Dow futures steady as AI scare cools, Nvidia earnings and Trump tariffs loom

Japan’s Nikkei jumped 2.2% to 58,583.12 and the S&P 500 closed up 0.8% as Wall Street rebounded from a tech-led selloff. Anthropic launched 10 new AI plug-ins, boosting partner stocks such as Thomson Reuters and FactSet. AMD shares rose after a $60 billion AI chip deal with Meta. The U.S. began collecting a temporary 10% global import tariff, with a possible increase to 15% under consideration.
25 February 2026
··········
HSBC Buybacks Put on Ice Until Capital Recovers After Hang Seng Deal

HSBC Buybacks Put on Ice Until Capital Recovers After Hang Seng Deal

HSBC will not launch new share buybacks until its core capital ratio returns to its 14–14.5% target, after the Hang Seng Bank privatisation cut it below that range in January. The bank reported 2025 pretax profit of $29.9 billion, down 7% after one-off charges but ahead of forecasts. HSBC shares rose as much as 4.1% in Hong Kong after the results. Management raised its profitability targets through 2028.
25 February 2026
·
Coles share price slips as earnings loom and ACCC “Down Down” court fight hangs over stock

Coles share price slips as earnings loom and ACCC “Down Down” court fight hangs over stock

Coles Group shares fell 0.2% to A$21.82 on Wednesday as the ACCC pressed its case alleging Coles misled shoppers with some “Down Down” promotions. Justice Michael O’Bryan questioned the regulator’s framing; the trial resumes Thursday. Coles reports interim results Friday, with analysts expecting sales near A$23.77 billion and underlying NPAT of A$680–700 million.
25 February 2026
···
Lynas Rare Earths share price jumps nearly 8% on ASX as results near and export curbs bite

Lynas Rare Earths share price jumps nearly 8% on ASX as results near and export curbs bite

Lynas Rare Earths (ASX:LYC) surged 7.9% to A$17.03 after China barred exports of key rare earth metals to 20 Japanese entities. The stock traded 7.66 million shares, up from a previous close of A$15.78. Investors await Lynas’s half-year results and CEO Amanda Lacaze’s briefing Thursday at 11 a.m. Sydney time. Rare earth prices, especially dysprosium and terbium, have climbed outside China.
25 February 2026
·
Woodside share price rises again as dividend lift and CEO hunt keep WDS in focus

Woodside share price rises again as dividend lift and CEO hunt keep WDS in focus

Woodside shares closed up 1.8% at A$28.24 on Wednesday, rising about 4% over two sessions after full-year results and a dividend update. Net profit fell 24% to $2.718 billion, while operating cash flow reached $7.2 billion. The company guided to 2026 production of 172–186 million barrels of oil equivalent and capital spending of $4.0–$4.5 billion. Investors await news on the CEO appointment and progress on LNG projects.
25 February 2026
···
Westpac share price rises: what’s driving WBC stock as RBA rate bets build

Westpac share price rises: what’s driving WBC stock as RBA rate bets build

Westpac shares rose 0.94% to A$43.05 as Australia’s core inflation hit a 16-month high at 3.4%, raising market bets of a May rate hike to 80%. The ASX 200 closed at a record 9,128.3. Brokers flagged caution on major bank valuations, with Morgan Stanley rating Westpac underweight. Investors await the Reserve Bank’s March policy meeting and Westpac’s May results.
25 February 2026
··
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 25.02.2026

Supernus Pharmaceuticals reported Q4 earnings of $0.92 per share, beating the Zacks estimate of $0.28. Revenue rose to $211.57 million from $174.16 million a year earlier. The company has topped consensus estimates for four straight quarters. Shares are up 2% year-to-date, but the stock holds a Zacks Rank #5 (Strong Sell) due to negative earnings estimate revisions.
25 February 2026
·
Tokyo stock market today: Nikkei hits new record as yen weakens and AI jitters ease

Tokyo stock market today: Nikkei hits new record as yen weakens and AI jitters ease

Japan’s Nikkei 225 rose 1.1% to a record 58,047.89 in early Wednesday trade, boosted by a weaker yen and steady AI sentiment. The yen fell to 155.74 per dollar after reports of political doubts over further Bank of Japan rate hikes. January’s services producer price index increased 2.6% year-on-year, matching December. Foreign investors bought a net 1.42 trillion yen of Japanese stocks in the week to Feb. 14.
25 February 2026
···
Mastercard stock price drops below $500 as viral AI report hits payment names

Mastercard stock price drops below $500 as viral AI report hits payment names

Mastercard shares fell 5.7% to $498 in after-hours trading Tuesday, with about 6.3 million shares changing hands. Visa dropped 4.5% and American Express slid 7.2% in the same session. The declines followed a widely circulated report warning of AI-driven job losses and margin pressure. Mastercard also announced a remittance partnership with Triple-A and the sale of SessionM to Capillary Technologies for $20 million.
25 February 2026
··
1 … 271 272 273 274 275 … 1,568

Stock Market Today

  • CervoMed Shares Surge on Dementia Drug Patent, Market Pulls Back on Equity Offering
    June 18, 2026, 4:08 PM EDT. CervoMed shares surged initially to $7.75 after U.S. patent allowance for neflamapimod in pure dementia with Lewy bodies (DLB) was announced, potentially protecting the drug through 2042. The company plans a $10 million registered direct equity offering at $4 per share, causing the stock to retrace gains and settle at $4.14. CervoMed aims to advance its oral DLB drug to late-stage trials, addressing an unmet need with no current approved treatments in the U.S. or EU. The equity raise, arranged by H.C. Wainwright, will support ongoing development and general corporate uses. The market reacted to the balance of intellectual property value against dilution risk. CervoMed's recent private placement extends its cash runway to Q2 2027, as it seeks a Phase 3 partner for neflamapimod.

Latest articles

CervoMed rises on patent news, pares gains after $10M equity sale

CervoMed rises on patent news, pares gains after $10M equity sale

18 June 2026
CervoMed shares soared to $7.75 intraday after announcing a U.S. patent allowance for neflamapimod in “pure” dementia with Lewy bodies patients, with protection expected into 2042, but gave back most gains after a $10 million share sale at $4 each; stock last up 8.7% at $4.14 on volume over 105 million shares.
Corning stock jumps 10% as AI data-center fiber trade draws fresh bids

Corning stock jumps 10% as AI data-center fiber trade draws fresh bids

18 June 2026
Corning shares soared 10.3% to $193.45 Thursday, outpacing the market as investors focused on its AI data-center optical-fiber deals with Amazon and Nvidia; core Q1 sales rose 18% to $4.35 billion, but risks remain from weak consumer demand and a high P/E ratio of 92, with the lowest analyst target at $180.
Amazon Shares Edge Higher, AI Chip Push Puts Spotlight on AWS Spend

Amazon Shares Edge Higher, AI Chip Push Puts Spotlight on AWS Spend

18 June 2026
Amazon shares jumped 2.4% after reports it’s in talks to sell its custom AI chips to other companies’ data centers, signaling a potential new revenue stream beyond AWS and raising investor hopes that Amazon’s heavy AI spending could soon deliver faster returns.
Go toTop